Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.

Kim SP, Crispen PL, Thompson RH, Weight CJ, Boorjian SA, Costello BA, Lohse CM, Leibovich BC.

Cancer. 2012 Sep 15;118(18):4412-20. doi: 10.1002/cncr.26695. Epub 2012 Jan 3.

2.

Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.

Wolff I, May M, Hoschke B, Zigeuner R, Cindolo L, Hutterer G, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Figenshau RS, Madison K, Sánchez-Chapado M, Santiago Martin MD, Salzano L, Lotrecchiano G, Shariat SF, Hohenfellner M, Waidelich R, Stief C, Miller K, Pahernik S, Brookman-May S; Members of the CORONA Project and the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group.

Eur J Surg Oncol. 2016 May;42(5):744-50. doi: 10.1016/j.ejso.2016.01.009. Epub 2016 Jan 22.

PMID:
26899942
5.

Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.

Stachowicz-Stencel T, Bien E, Balcerska A, Godzinski J, Synakiewicz A, Perek-Polnik M, Kurylak A, Pietras W, Kuzmicz M, Mizia-Malarz A, Rybczynska A, Nurzynska-Flak J.

Klin Padiatr. 2011 May;223(3):138-41. doi: 10.1055/s-0031-1275349. Epub 2011 Apr 20.

PMID:
21509711
6.

Current clinical trials in renal cell carcinoma.

Sokoloff MH, Daneshmand S, Ryan CW.

Urol Oncol. 2005 Jul-Aug;23(4):289-92. Review.

PMID:
16018946
7.

Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.

Sandhu SS, Symes A, A'Hern R, Sohaib SA, Eisen T, Gore M, Christmas TJ.

BJU Int. 2005 Mar;95(4):522-5.

8.

Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.

Homicsko K, Berthold DR.

Anticancer Drugs. 2011 Jan;22 Suppl 1:S4-8. doi: 10.1097/01.cad.0000390766.47540.07. Review.

PMID:
21173604
9.

Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.

Repmann R, Goldschmidt AJ, Richter A.

Anticancer Res. 2003 Mar-Apr;23(2A):969-74. Erratum in: Anticancer Res. 2003;23:5370.

PMID:
12820332
10.

The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?

Sciarra A, Cattarino S, Salciccia S, Alfarone A, Gentilucci A, Parente U, Mariotti G, Innocenzi M, Gentile V.

Crit Rev Oncol Hematol. 2012 Feb;81(2):151-62. doi: 10.1016/j.critrevonc.2011.02.003. Epub 2011 Mar 8. Review.

PMID:
21388825
11.

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.

Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG.

Cancer. 2008 Apr 1;112(7):1480-8. doi: 10.1002/cncr.23322.

12.

Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.

Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H.

Urology. 2003 Oct;62(4):641-6. Review.

PMID:
14550434
13.

[Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].

Doehn C, Merseburger AS, Jocham D, Kuczyk MA.

Urologe A. 2007 Oct;46(10):1371-2, 1374, 1376-8. German.

PMID:
17805507
14.

Neoadjuvant and adjuvant treatment of renal cell carcinoma.

Thillai K, Allan S, Powles T, Rudman S, Chowdhury S.

Expert Rev Anticancer Ther. 2012 Jun;12(6):765-76. doi: 10.1586/era.12.56. Review.

PMID:
22716493
15.

Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.

Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P.

J Clin Oncol. 2006 Jul 1;24(19):3101-6.

PMID:
16809736
16.

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H.

Cancer. 2003 Apr 1;97(7):1663-71.

17.

The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.

Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, Simeone C.

BJU Int. 2007 Feb;99(2):296-300.

PMID:
17326263
18.

Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.

Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA.

Urology. 2011 Nov;78(5):1101-6. doi: 10.1016/j.urology.2011.05.012. Epub 2011 Sep 8.

PMID:
21903243
19.

Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.

Tan MH, Kanesvaran R, Li H, Tan HL, Tan PH, Wong CF, Chia KS, Teh BT, Yuen J, Chong TW.

Urology. 2010 Jun;75(6):1365-1370; 1370.e1-3. doi: 10.1016/j.urology.2009.07.1289.

PMID:
20022084
20.

[CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].

Nosov AK, Novik AV, Vorobiev AV, Samartseva EE, Reva SA, Baldueva IA, Lushina PA.

Vopr Onkol. 2015;61(3):494-8. Russian.

PMID:
26242167

Supplemental Content

Support Center